Bluejay Diagnostics Net Income
| BJDX Stock | USD 2.67 0.05 1.84% |
As of the 14th of February 2026, Bluejay Diagnostics shows the Mean Deviation of 4.35, risk adjusted performance of (0.14), and Standard Deviation of 6.06. Bluejay Diagnostics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
Bluejay Diagnostics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Bluejay Diagnostics' valuation are provided below:We have found one hundred twenty available fundamental signals for Bluejay Diagnostics, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to validate all of Bluejay Diagnostics prevailing market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. | Last Reported | Projected for Next Year | ||
| Net Loss | -6.9 M | -7.3 M | |
| Net Loss | -8.4 M | -7.9 M | |
| Net Loss | -6.9 M | -7.3 M | |
| Net Loss | (193.58) | (203.26) | |
| Net Income Per E B T | 0.96 | 0.79 |
Bluejay | Net Income | Build AI portfolio with Bluejay Stock |
The evolution of Net Income for Bluejay Diagnostics provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Bluejay Diagnostics compares to historical norms and industry peers.
Latest Bluejay Diagnostics' Net Income Growth Pattern
Below is the plot of the Net Income of Bluejay Diagnostics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Bluejay Diagnostics financial statement analysis. It represents the amount of money remaining after all of Bluejay Diagnostics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Bluejay Diagnostics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Bluejay Diagnostics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (7.72 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Bluejay Net Income Regression Statistics
| Arithmetic Mean | (3,155,325) | |
| Coefficient Of Variation | (111.54) | |
| Mean Deviation | 3,059,494 | |
| Median | (757,716) | |
| Standard Deviation | 3,519,436 | |
| Sample Variance | 12.4T | |
| Range | 9.2M | |
| R-Value | (0.80) | |
| Mean Square Error | 4.8T | |
| R-Squared | 0.64 | |
| Significance | 0.0001 | |
| Slope | (556,748) | |
| Total Sum of Squares | 198.2T |
Bluejay Net Income History
Other Fundumenentals of Bluejay Diagnostics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Bluejay Diagnostics Net Income component correlations
Bluejay Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Bluejay Diagnostics is extremely important. It helps to project a fair market value of Bluejay Stock properly, considering its historical fundamentals such as Net Income. Since Bluejay Diagnostics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Bluejay Diagnostics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Bluejay Diagnostics' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bluejay Diagnostics. Projected growth potential of Bluejay fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Bluejay Diagnostics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Understanding Bluejay Diagnostics requires distinguishing between market price and book value, where the latter reflects Bluejay's accounting equity. The concept of intrinsic value - what Bluejay Diagnostics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Bluejay Diagnostics' price substantially above or below its fundamental value.
It's important to distinguish between Bluejay Diagnostics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Bluejay Diagnostics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Bluejay Diagnostics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Bluejay Diagnostics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Bluejay Diagnostics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Bluejay Diagnostics.
| 11/16/2025 |
| 02/14/2026 |
If you would invest 0.00 in Bluejay Diagnostics on November 16, 2025 and sell it all today you would earn a total of 0.00 from holding Bluejay Diagnostics or generate 0.0% return on investment in Bluejay Diagnostics over 90 days. Bluejay Diagnostics is related to or competes with Tivic Health, Catheter Precision, Universe Pharmaceuticals, BriaCell Therapeutics, Moolec Science, Elevai Labs, and GeneDx Holdings. Bluejay Diagnostics, Inc., a diagnostic company, develops and markets patient products for triage, diagnosis, and monito... More
Bluejay Diagnostics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Bluejay Diagnostics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Bluejay Diagnostics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.20) | |||
| Maximum Drawdown | 33.72 | |||
| Value At Risk | (8.72) | |||
| Potential Upside | 8.66 |
Bluejay Diagnostics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Bluejay Diagnostics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Bluejay Diagnostics' standard deviation. In reality, there are many statistical measures that can use Bluejay Diagnostics historical prices to predict the future Bluejay Diagnostics' volatility.| Risk Adjusted Performance | (0.14) | |||
| Jensen Alpha | (1.26) | |||
| Total Risk Alpha | (1.57) | |||
| Treynor Ratio | (0.49) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Bluejay Diagnostics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Bluejay Diagnostics February 14, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.14) | |||
| Market Risk Adjusted Performance | (0.48) | |||
| Mean Deviation | 4.35 | |||
| Coefficient Of Variation | (544.13) | |||
| Standard Deviation | 6.06 | |||
| Variance | 36.72 | |||
| Information Ratio | (0.20) | |||
| Jensen Alpha | (1.26) | |||
| Total Risk Alpha | (1.57) | |||
| Treynor Ratio | (0.49) | |||
| Maximum Drawdown | 33.72 | |||
| Value At Risk | (8.72) | |||
| Potential Upside | 8.66 | |||
| Skewness | 1.51 | |||
| Kurtosis | 4.42 |
Bluejay Diagnostics Backtested Returns
Bluejay Diagnostics secures Sharpe Ratio (or Efficiency) of -0.18, which signifies that the company had a -0.18 % return per unit of risk over the last 3 months. Bluejay Diagnostics exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Bluejay Diagnostics' Mean Deviation of 4.35, standard deviation of 6.06, and Risk Adjusted Performance of (0.14) to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 2.3, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Bluejay Diagnostics will likely underperform. At this point, Bluejay Diagnostics has a negative expected return of -1.07%. Please make sure to confirm Bluejay Diagnostics' total risk alpha, kurtosis, as well as the relationship between the Kurtosis and day typical price , to decide if Bluejay Diagnostics performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.53 |
Good reverse predictability
Bluejay Diagnostics has good reverse predictability. Overlapping area represents the amount of predictability between Bluejay Diagnostics time series from 16th of November 2025 to 31st of December 2025 and 31st of December 2025 to 14th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Bluejay Diagnostics price movement. The serial correlation of -0.53 indicates that about 53.0% of current Bluejay Diagnostics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.53 | |
| Spearman Rank Test | -0.61 | |
| Residual Average | 0.0 | |
| Price Variance | 0.1 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Bluejay Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Bluejay Diagnostics reported net income of (7.72 Million). This is 102.26% lower than that of the Health Care Equipment & Supplies sector and 103.24% lower than that of the Health Care industry. The net income for all United States stocks is 101.35% higher than that of the company.
Bluejay Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bluejay Diagnostics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Bluejay Diagnostics could also be used in its relative valuation, which is a method of valuing Bluejay Diagnostics by comparing valuation metrics of similar companies.Bluejay Diagnostics is currently under evaluation in net income category among its peers.
Bluejay Diagnostics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Bluejay Diagnostics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Bluejay Diagnostics' managers, analysts, and investors.Environmental | Governance | Social |
Bluejay Diagnostics Institutional Holders
Institutional Holdings refers to the ownership stake in Bluejay Diagnostics that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Bluejay Diagnostics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Bluejay Diagnostics' value.| Shares | Sabby Management Llc | 2025-06-30 | 96 K | Tower Research Capital Llc | 2025-06-30 | 2.3 K | Ubs Group Ag | 2025-06-30 | 444 | Citigroup Inc | 2025-06-30 | 241 | Bank Of America Corp | 2025-06-30 | 5.0 | Sbi Securities Co Ltd | 2025-06-30 | 0.0 |
Bluejay Fundamentals
| Return On Equity | -1.26 | ||||
| Return On Asset | -0.66 | ||||
| Current Valuation | (1.01 M) | ||||
| Shares Outstanding | 708.53 K | ||||
| Shares Owned By Insiders | 11.23 % | ||||
| Shares Owned By Institutions | 3.03 % | ||||
| Number Of Shares Shorted | 25.68 K | ||||
| Price To Book | 0.52 X | ||||
| Price To Sales | 54.99 X | ||||
| Gross Profit | 48.91 K | ||||
| EBITDA | (6.7 M) | ||||
| Net Income | (7.72 M) | ||||
| Cash And Equivalents | 15.34 M | ||||
| Cash Per Share | 0.76 X | ||||
| Total Debt | 222.25 K | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 17.41 X | ||||
| Book Value Per Share | 9.01 X | ||||
| Cash Flow From Operations | (7.82 M) | ||||
| Short Ratio | 0.28 X | ||||
| Earnings Per Share | 657.48 X | ||||
| Target Price | 256.0 | ||||
| Beta | 0.67 | ||||
| Market Capitalization | 1.93 M | ||||
| Total Asset | 6.66 M | ||||
| Retained Earnings | (34.67 M) | ||||
| Working Capital | 4.09 M | ||||
| Net Asset | 6.66 M |
About Bluejay Diagnostics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bluejay Diagnostics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bluejay Diagnostics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bluejay Diagnostics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Bluejay Stock Analysis
When running Bluejay Diagnostics' price analysis, check to measure Bluejay Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bluejay Diagnostics is operating at the current time. Most of Bluejay Diagnostics' value examination focuses on studying past and present price action to predict the probability of Bluejay Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bluejay Diagnostics' price. Additionally, you may evaluate how the addition of Bluejay Diagnostics to your portfolios can decrease your overall portfolio volatility.